Thu, Apr 24, 2025
[Archive]
Volume 33, Issue 156 (January & February 2025)
J Adv Med Biomed Res 2025, 33(156): 1-10 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ziaie N, Hamidia A, Ramezani A, Abrtan S, Shirafkan H, Hadizadeh H, et al . The Comparison of the Efficacy of Agomelatine and Sertraline Medications in the Treatment of Depressive Symptoms in Patients with Heart Failure: A Randomized Double-Blind Clinical Trial. J Adv Med Biomed Res 2025; 33 (156) :1-10
URL: http://journal.zums.ac.ir/article-1-7484-en.html
URL: http://journal.zums.ac.ir/article-1-7484-en.html
Naghmeh Ziaie1 
, Angela Hamidia2 , Azadeh Ramezani3 , Saeed Abrtan3 , Hoda Shirafkan4 , Hirbod Hadizadeh5 , Negin Tavakoli5 , Romina Hamzehpour *6
, Angela Hamidia2 , Azadeh Ramezani3 , Saeed Abrtan3 , Hoda Shirafkan4 , Hirbod Hadizadeh5 , Negin Tavakoli5 , Romina Hamzehpour *6
1- Department of Cardiology Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran
2- Department of Psychiatry, Social Determinants of Health Research Center, Babol University of Medical Sciences, Babol, Iran
3- Department of Psychiatry, School of Medicine, Babol University of Medical Sciences, Babol, Iran
4- Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical sciences, Babol, Iran
5- Student Research Committee, Babol University of Medical Sciences, Babol, Iran
6- Department of Psychiatry, Social Determinants of Health Research Center, Babol University of Medical Sciences, Babol, Iran ,rominahamzehpour@gmail.com
2- Department of Psychiatry, Social Determinants of Health Research Center, Babol University of Medical Sciences, Babol, Iran
3- Department of Psychiatry, School of Medicine, Babol University of Medical Sciences, Babol, Iran
4- Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical sciences, Babol, Iran
5- Student Research Committee, Babol University of Medical Sciences, Babol, Iran
6- Department of Psychiatry, Social Determinants of Health Research Center, Babol University of Medical Sciences, Babol, Iran ,
Abstract: (250 Views)
Objectives & Aims: Depression impacts 20% of heart failure (HF) patients, doubling their mortality risk and tripling non-compliance with treatment. This study compares the effectiveness of Agomelatine and Sertraline in treating depression in these patients.
Methods: This double-blind, randomized clinical trial study was conducted on 58 patients referred to Babol University of Medical Sciences clinics. The participants were divided into two groups of 29 samples; one group was treated with Sertraline (half a 25 mg tablet) and the other with Agomelatine (a daily 25 mg tablet) for 12 weeks. Evaluation of depression scores before the intervention and in weeks 4, 8, and 12 was done by BDI-II and HAM-D questionnaires.
Results: The mean age of the patients was 61.59±15.32 years, and 17 (58.6%) participants were female. An analysis of the BDI-II and HAM-D questionnaire scores in both groups revealed a significant effect of time (P<0.001), indicating that scores on both questionnaires decreased significantly over time. However, the treatment group's effect was insignificant (p=0.538, p=0.412). Regarding side effects, no significant differences were observed between the two medications (all P>0.05).
Conclusion: This study's findings indicate that Agomelatine and Sertraline are not superior in managing depression in HF patients. Most secondary outcomes and side effect profiles were similar between the two treatment groups, with no significant differences observed. Additionally, the efficacy of both medications remained consistent across HF patients with varying disease severity.
Type of Study: Clinical Trials |
Subject:
Epidemiologic Studies
Received: 2024/11/21 | Accepted: 2025/03/3 | Published: 2025/03/13
Received: 2024/11/21 | Accepted: 2025/03/3 | Published: 2025/03/13
References
1. Khan N, Akbar A, Fahad S, Faisal S, Naushad M. Analysis of heart treatment and its impact on socioeconomic conditions on the world community. Available at SSRN 3727588. 2020;9. [DOI:10.2139/ssrn.3727588]
2. Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2021;18(6):400-23. [DOI:10.1038/s41569-020-00480-6] [PMID] [PMCID]
3. Rohde LE, Zimerman A, Vaduganathan M, Claggett BL, Packer M, Desai AS, et al. Associations between New York heart association classification, objective measures, and long-term prognosis in mild heart failure: a secondary analysis of the PARADIGM-HF trial. JAMA Cardiol. 2023;8(2):150-8. [DOI:10.1001/jamacardio.2022.4427] [PMID] [PMCID]
4. Covid C, Team R, Chow N, Fleming-Dutra K, Gierke R, Hall A, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States, February 12-March 28, 2020. Morb Mortal Wkly Rep. 2020;69(13):382. [DOI:10.15585/mmwr.mm6913e2] [PMID] [PMCID]
5. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527-37. [DOI:10.1016/j.jacc.2006.06.055] [PMID]
6. Easton K, Coventry P, Lovell K, Carter LA, Deaton C. Prevalence and measurement of anxiety in samples of patients with heart failure: meta-analysis. J Cardiovasc Nurs. 2016;31(4):367-79. [DOI:10.1097/JCN.0000000000000265] [PMID] [PMCID]
7. Sullivan M, Levy WC, Russo JE, Spertus JA. Depression and health status in patients with advanced heart failure: a prospective study in tertiary care. J Card Fail. 2004;10(5):390-6. [DOI:10.1016/j.cardfail.2004.01.011] [PMID]
8. Koirala B, Himmelfarb CR, Budhathoki C, Davidson PM. Heart failure self-care, factors influencing self-care and the relationship with health-related quality of life: A cross-sectional observational study. Heliyon. 2020;6(2):e03412. [DOI:10.1016/j.heliyon.2020.e03412] [PMID] [PMCID]
9. Moser DK, Watkins JF. Conceptualizing self-care in heart failure: a life course model of patient characteristics. J Cardiovasc Nurs. 2008;23(3):205-18. [DOI:10.1097/01.JCN.0000305097.09710.a5] [PMID]
10. Wang Z, Tocchi C, Chyun D, Kim K, Cong X, Starkweather A. The association between psychological factors and self-care in patients with heart failure: an integrative review. Eur J Cardiovasc Nurs. 2023;22(6):553-61. [DOI:10.1093/eurjcn/zvac106] [PMID]
11. Hu T, Zhao X, Wu M, Li Z, Luo L, Yang C, et al. Prevalence of depression in older adults: A systematic review and meta-analysis. Psychiatry Res. 2022;311:114511. [DOI:10.1016/j.psychres.2022.114511] [PMID]
12. Faris R, Purcell H, Henein MY, Coats AJ. Clinical depression is common and significantly associated with reduced survival in patients with non‐ischaemic heart failure. Eur J Heart Fail. 2002;4(4):541-51. [DOI:10.1016/S1388-9842(02)00101-0] [PMID]
13. IsHak WW, Hamilton MA, Korouri S, Diniz MA, Mirocha J, Hedrick R, et al Comparative Effectiveness of Psychotherapy vs Antidepressants for Depression in Heart Failure: A Randomized Clinical Trial. JAMA Netw Open. 2024;7(1):e2352094-. [DOI:10.1001/jamanetworkopen.2023.52094] [PMID] [PMCID]
14. Pierre Olié J, Kasper S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol. 2007;10(5):661-73. [DOI:10.1017/S1461145707007766] [PMID]
15. Fornaro M, Prestia D, Colicchio S, Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol. 2010;8(3):287-304. [DOI:10.2174/157015910792246227] [PMID] [PMCID]
16. Hong N, Ye Z, Lin Y, Liu W, Xu N, Wang Y. Agomelatine prevents angiotensin II-induced endothelial and mononuclear cell adhesion. Aging (albany NY). 2021;13(14):18515. [DOI:10.18632/aging.203299] [PMID] [PMCID]
17. Ghosh RK, Ball S, Prasad V, Gupta A. Depression in heart failure: Intricate relationship, pathophysiology and most updated evidence of interventions from recent clinical studies. Int J Cardiol. 2016;224:170-7. [DOI:10.1016/j.ijcard.2016.09.063] [PMID]
18. Sokoreli I, De Vries JJ, Pauws SC, Steyerberg EW. Depression and anxiety as predictors of mortality among heart failure patients: systematic review and meta-analysis. Heart Fail Rev. 2016;21:49-63. [DOI:10.1007/s10741-015-9517-4] [PMID]
19. Sadock BJ. Kaplan & Sadock's synopsis of psychiatry: behavioral sciences/clinical psychiatry. Philadelphia, PA: Wolters Kluwer; 2015.
20. Luo X, Zhu D, Li J, Ren M, Liu Y, Si T, et al. Selection of the optimal dose of sertraline for depression: A dose-response meta-analysis of randomized controlled trials. Psychiatry Res. 2023;327:115391. [DOI:10.1016/j.psychres.2023.115391] [PMID]
21. Stein DJ, Khoo JP, Picarel-Blanchot F, Olivier V, Van Ameringen M. Efficacy of agomelatine 25-50 mg for the treatment of anxious symptoms and functional impairment in generalized anxiety disorder: a meta-analysis of three placebo-controlled studies. Adv Ther. 2021;38:1567-83. [DOI:10.1007/s12325-020-01583-9] [PMID] [PMCID]
22. McConnell S, Jacka FN, Williams LJ, Dodd S, Berk M. The relationship between depression and cardiovascular disease. Int J Psychiatry Clin Pract. 2005;9(3):157-67. [DOI:10.1080/13651500510029138] [PMID]
23. Fadhil A, Saleh-Arong H, Chokemaitree N, Nata N, Tasanavipas P, Varothai N, et al. Effect of agomelatine and sertraline on patients with major depressive disorders and chronic kidney disease: a randomized controlled trial. J South Asian Med Res. 2022;6:e0127. [DOI:10.55374/jseamed.v6i0.127]
24. Medvedev VE, Korovyakova EA, Frolova VI, Gushanskaya EV. Antidepressant therapy in patients with cardiovascular diseases. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(1):131-40.25. [DOI:10.14412/2074-2711-2019-1-131-140]
25. Goodwin G, Rouillon F, Emsley R. Long-term treatment with agomelatine: prevention of relapse in patients with major depressive disorder over 10 months. Eur Neuropsychopharmacol. 2008;18:S338-9. [DOI:10.1016/S0924-977X(08)70471-1]
26. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ. 2014;348:g1888. [DOI:10.1136/bmj.g1888] [PMID] [PMCID]
27. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-66. [DOI:10.1016/S0140-6736(17)32802-7]
28. Oliva V, Lippi M, Paci R, Del Fabro L, Delvecchio G, Brambilla P, et al. Gastrointestinal side effects associated with antidepressant treatments in patients with major depressive disorder: A systematic review and meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2021;109:110266. [DOI:10.1016/j.pnpbp.2021.110266] [PMID]
29. Smeraldi E, Delmonte D. Agomelatine in depression. Expert opinion on drug safety. 2013;12(6):873-80. [DOI:10.1517/14740338.2013.828690] [PMID]
30. Karaiskos D, Tzavellas E, Ilias I, Liappas I, Paparrigopoulos T. Agomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus. Int J Clin Pract Suppl. 2013;67(3):257-60. [DOI:10.1111/ijcp.12112] [PMID]
31. Ahmadvand A, Sepehrmanesh Z, Karizno MB, Rahimi H. Comparing the effect of agomelatine and sertraline in treating patients with major depression disorder. Int Arch Health Sci. 2023;10(3):122-9.
32. Kubanek A, Przybylak M, Paul P, Kowalska AS, Błaszczyk M, Macul-Sanewska A, et al. Use of sertraline and agomelatine in hemodialysis patients: A case series report. Acta Biochim Pol. 2023;70(4):979-83. [DOI:10.18388/abp.2020_6936] [PMID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Copyright Policy
